Retigabine
Drug
Retigabine or ezogabine is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients. The drug was developed by Valeant Pharmaceuticals and GlaxoSmithKline. Wikipedia
AHFS/Drugs.com: Professional Drug Facts
ATC code: N03AX21 (WHO)
Metabolism: Liver glucuronidation and acetylation. CYP not involved
Other names: D-23129, ezogabine (USAN US)
Protein binding: 60–80%